Regarding efficacy, it is clear that the combined therapy of IFX and AZA has more effectiveness compared with either drug monotherapy for inducing clinical remission and mucosal healing in CD and UC [42, 82]
(2013) 304:C1709
Alvarez ME, Pennell RI, Meijer PJ, Ishikawa A, Dixon RA, Lamb C
Disclosures: Tassos Grammatikopoulos: Nothing to Disclose, Reha Artan: Nothing to Disclose, Pier Luigi Calvo: Nothing to Disclose, Piotr Czubkowski: IPSEN: Consultant, Buket Dalgic: Nothing to Disclose, Lorenzo D'Antiga: Selecta: Advisor, Vivet: Advisor, Spark: Advisor, Genespire: Advisor, Tome: Advisor, Mirum: Advisor, Ipsen/Albireo: Advisor, Intercept/Advanz Pharma: Advisor, Alexion/Astra Zeneca: Advisor, Ozlem Durmaz: Nothing to Disclose, Emmanuel Gonzales: Nothing to Disclose, Girish Gupte: Albireo: Grant/Research Support, Winita Hardikar: Ipsen: Advisor, Binita Kamath: Mirum: Consultant, Mirum: Grant/Research Support, Albireo/Ipsen: Consultant, Albireo/Ipsen: Grant/Research Support, Audentes: Consultant, Florence Lacaille: Nothing to Disclose, Cara Mack: Nothing to Disclose, Patrick McKiernan: Nothing to Disclose, Hasan zen: Nothing to Disclose, Sanjay Rajwal: Nothing to Disclose, Mathias Ruiz: Nothing to Disclose, Mohammad Shagrani: Nothing to Disclose, Eyal Shteyer: Nothing to Disclose, Nisreen Soufi: Mirum Pharmaceuticals: Advisor, Mary Elizabeth Tessier: Albireo/Ipsen: site PI for a pharmaceutical study, Albireo: site PI for a pharmaceutical study, Wendy Van Der Woerd: Mirum pharma: Consultant, Fatine Elaraki: Nothing to Disclose, Tao Gu: Nothing to Disclose, Michelle Hammerschmidt: Nothing to Disclose, Alejandra Ramirez-Santiago: Nothing to Disclose, Terese Wallefors: Nothing to Disclose, Douglas Silveira: Nothing to Disclose, Henkjan Verkade: Mirum: Grant/Research Support, Mirum: Consultant, Mirum: Speaking and Teaching, Ipsen / Albireo: Consultant, Ipsen / Albireo: Grant/Research Support, Ipsen / Albireo: Speaking and Teaching, Intercept: Consultant, Orphalan: Consultant 2349 AN INTERNATIONAL STUDY OF CIRCULATING FIBROSIS AND INFLAMMATORY MARKERS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS Maryam Yazdanfar 1 Richard Dean 2 Joseph Zepeda 2 Sandeep Dhaliwal 2 Chung Heng Liu 2 Christina Ebert 3 Yi Luo 3 Lei Zhao 3 Palak Trivedi 4 Christopher Bowlus 5 , 1 University of California Davis School of Medicine, 2 University of California Davis, 3 Bristol-Myers Squibb, 4 University of Birmingham, 5 University of California, Davis Background: Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease with a variable progression to cirrhosis, cholangiocarcinoma, and hepatic decompensation
Zwergel, C., Valente, S
